# US 2023/0417764 A1 · Methods for treating drug resistant cancers

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0417764 A1
- Document ID: US20230417764A1
- Status: Published application
- Kind: A1
- Application number: 18/195,184
- Filed: 2023-05-09
- Published: 2023-12-28
- Earliest claimed: 2017-06-14
- Assignees: The Regents of the University of California
- Applicants: The Regents of the University of California
- Inventors: David CHERESH; Sara Weis; Erika COSSET
- Web page: https://patentgrep.com/patent/US20230417764A1

## CPC

- G01N 33/6872: {Intracellular protein regulatory factors and their receptors, e.g. including ion channels}
- A61K 38/07: Tetrapeptides
- A61K 38/12: Cyclic peptides {, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C (A61K38/043 - A61K38/046 take precedence)}
- C07K 14/70546: {Integrin superfamily}
- C07K 14/70557: {Integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61}
- C07K 16/2848: {against integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61}
- C07K 16/2863: {against receptors for growth factors, growth regulators}
- C07K 16/30: from tumour cells
- G01N 33/575: for cancer
- G01N 33/5759: {involving compounds localised on the membrane of tumour or cancer cells}
- C07K 2317/569: Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
- C07K 2317/622: Single chain antibody (scFv)
- G01N 2333/70557: Integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61
- G01N 2800/52: Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

Provided are methods for determining whether a glioblastoma (GBM) tumor or GBM cancer cell will be sensitive to a treatment targeting the integrin avb3 (αvβ3) pathway, comprising determining whether the GBM tumor or the GBM cancer cell expresses both avb3+ and Glut3+ along with a specific genetic signature associated with Glut3 addiction, where in alternative embodiments a cell is Glut3 addiction if the GBM tumor or the GBM cancer cell has markers consistent with the Classical or the Proneural molecular subtypes of GBM, or, expresses markers consistent with a Glut3-addicted molecular signature, e.g., as listed in FIG. 11 or FIG. 23. Also provided herein are methods of treating glioblastoma (GBM) tumors found to be sensitive to agents targeting or inhibiting the integrin avb3 (αvβ3) pathway, wherein the sensitivity is determined by methods as provided herein.

## Claims

### Claim 1

A method for determining whether a tumor or a cancer cell will be sensitive to (or can be killed or induced to senescence by) a treatment targeting the integrin avb3 (αvβ3) pathway, comprising:
(a) determining or having determined whether the tumor or the cancer cell expresses both avb3+ and Glut3+, or determining whether the tumor or the cancer cell is a avb3+/Glut3+ tumor or cancer cell, and
(b) determining or having determined whether the tumor or the cancer cell is Glut-3 addicted,
wherein optionally determining or having determined whether the tumor or the cancer cell is Glut-3 addicted comprises:
(i) determining or having determined whether the tumor or the cancer cell expresses a marker (e.g., an mRNA or a protein) consistent with a Classical or Proneural subtype, e.g., expresses a marker consistent with the Classical or Proneural molecular subtypes of GBM,
wherein optionally the marker consistent with a Classical or Proneural subtype comprises an EGFR, GLI1, NES, DLL3 or OLIG2 gene transcript or an EGFR, GLI1, NES, DLL3 or OLIG2 protein, or
(ii) determining or having determined whether the tumor or the cancer cell expresses (e.g., expresses mRNA or protein) consistent with a Glut3 addicted gene signature,
wherein optionally gene expression consistent with a Glut3 addicted gene signature comprises gene expression consistent with a high (a Glut3 addicted signature) or low (a Glut3 non-addicted signature) expression of at least one (one or more) of the genes, or 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29 or all 30 of the genes, as listed in FIG. 11 or FIG. 23, or optionally all of the genes listed in FIG. 11 or FIG. 23,
wherein if a tumor or a cancer cell expresses both avb3+ and Glut3+ and is Glut-3 addicted, the tumor or the cancer cell will be sensitive to (will be substantially sensitive to) or will be successfully treated by (e.g., can be killed or induced to senescence by) the treatment targeting the integrin avb3 (αvβ3) pathway,
wherein optionally the tumor or cancer cell is a glioblastoma (GBM) tumor or cell, a melanoma tumor or melanoma cell or a primitive neuroectodermal tumor (PNET) or PNET cell.

### Claim 2 (depends on 1)

The method of claim 1, wherein the treatment targeting the integrin avb3 (αvβ3) pathway targets avb3, Glut3, PAK4, or YAP/TAZ.

### Claim 3 (depends on 2)

The method of claim 2, wherein the treatment comprises administering or having administered to an individual in need thereof cilengitide (or, 2-[(2S,5R,8S,11S)-5-benzyl-11-{3-[(diaminomethylidene)amino]propyl}-7-methyl-3,6,9,12,15-pentaoxo-8-(propan-2-yl)-1,4,7,10,13-pentaazacyclopentadecan-2-yl]acetic acid).

### Claim 4

The method of any of the preceding claims, wherein the determining or having determined if the tumor or the cancer cell expresses both avb3+ and Glut3+ comprises determining if the tumor or the cancer cell expresses both an avb3+ and a Glut3+ protein, or both an avb3+ and a Glut3+ message (mRNA, transcript), or both an avb3+ and a Glut3+ protein and message,
and optionally the determining or having determined if the tumor or the cancer cell expresses both an avb3+ and a Glut3+ protein is by a method comprising use of antibodies that specifically bind to a protein of the integrin avb3 pathway, optionally comprising an avb3, Glut3, PAK4, or YAP/TAZ binding antibody (an antibody that specifically binds avb3, Glut3, PAK4, or YAP/TAZ),
and optionally the determining or having determined if the tumor or the cancer cell expresses both an avb3+ and a Glut3+ message (mRNA, transcript) is by a method comprising use of a polymerase chain reaction (PCR) (optionally comprising use of primers capable of amplifying an avb3+ and a Glut3+ message); or, gene expression profiling, an array, or a probe hybridization to a message, optionally a Northern blot (optionally comprising use of primers capable of specifically hybridizing to) an avb3+ and a Glut3+ message).

### Claim 5

The method of any of the preceding claims, wherein the determining or having determined if the tumor or the cancer cell expresses a marker consistent with a Classical or Proneural subtype or has a Glut3 addicted gene/molecular signature, optionally expressing at least one of the genes at levels as listed in FIG. 11 or FIG. 23, comprises determining or having determined if the tumor or the cancer cell expresses an mRNA and/or a protein consistent with a Classical or a Proneural subtype, or has a Glut3 addicted gene/molecular signature, optionally expressing an mRNA or protein from a gene as listed in FIG. 11 or FIG. 23,
and optionally the determining or having determined if the tumor or the cancer cell expresses a protein consistent with a Classical or a Proneural subtype, or has a Glut3 addicted gene/molecular signature, optionally expressing a protein from a gene as listed in FIG. 11 or FIG. 23, is by a method comprising use of antibodies that specifically bind to a protein consistent with a Classical or a Proneural subtype, or a protein from a gene as listed in FIG. 11 or FIG. 23,
and optionally the determining or having determined if the tumor or the cancer cell expresses a message (mRNA, transcript) consistent with a Classical or a Proneural subtype, or has a Glut3 addicted gene/molecular signature, optionally expressing an mRNA from a gene as listed in FIG. 11 or FIG. 23, is by a method comprising use of a polymerase chain reaction (PCR) (optionally comprising use of primers capable of amplifying a message (mRNA, transcript) consistent with a Classical or a Proneural subtype, or has a Glut3 addicted gene/molecular signature, optionally an mRNA from a gene as listed in FIG. 11 or FIG. 23); or, by gene expression profiling, optionally by using an array, or optionally by using a probe hybridization to a message of interest, optionally a Northern blot (optionally comprising use of primers capable of specifically hybridizing to) a message (mRNA, transcript) consistent with a Classical or a Proneural subtype, or optionally an mRNA from a gene as listed in FIG. 11 or FIG. 23.

### Claim 6

The method of any of the preceding claims, wherein the determining or having determined if the tumor or the cancer cell expresses both avb3+ and Glut3+ comprises taking or isolating a cell or a sample of cells, optionally cancer cells or tumors cells, from a patient, optionally a patient tentatively diagnosed or definitely diagnosed with the tumor or cancer, optionally GBM, and determining if the cell or sample of cells expresses both avb3+ and Glut3+ and is Glut-3 addicted.

### Claim 7 (depends on 1)

A method for treating or ameliorating, or killing, or inducing into senescence, a tumor or a cancer cell in a patient or ex vivo, wherein optionally the tumor or cancer cell is a glioblastoma (GBM) tumor or a GBM cancer cell, or a melanoma or a primitive neuroectodermal tumor (PNET), or treating or ameliorating a tumor or cancer, optionally GBM, a melanoma or a primitive neuroectodermal tumor (PNET), in an individual in need thereof, comprising:
(a) determining or having determined whether the tumor or cancer, optionally a glioblastoma (GBM) tumor or a GBM cancer cell, will be sensitive to a treatment targeting the integrin avb3 (αvβ3) pathway using a method of claim 1, and
(b) if the method of step (a) determines, or has had determined, that the tumor or cancer, optionally a glioblastoma (GBM) tumor or a GBM cancer cell, will be sensitive to a treatment targeting the integrin avb3 (αvβ3) pathway, administering or having administered the treatment targeting the integrin avb3 (αvβ3) pathway to an individual in need thereof, or,
administering or having administered the treatment to the tumor or cancer cell,
optionally to a glioblastoma (GBM) tumor or GBM cancer cell, if the tumor or cancer cell is derived from or isolated from the individual in need thereof, or if the tumor or cancer cell is determined to be sensitive to a treatment targeting the integrin avb3 (αvβ3) pathway using a method of claim 1 (e.g., if the glioblastoma (GBM) tumor or the GBM cancer cell is found to express both avb3+ and Glut3+ and is Glut-3 addicted).

### Claim 8 (depends on 7)

The method of claim 7, wherein the treatment targets avb3, Glut3, PAK4, or YAP/TAZ.

### Claim 9 (depends on 7)

The method of claim 7, wherein the treatment comprises administering or having administered to an individual in need thereof cilengitide (or, 2-[(2S,5R,8S,115)-5-benzyl-11-{3-[(diaminomethylidene)amino]propyl}-7-methyl-3,6,9,12,15-pentaoxo-8-(propan-2-yl)-1,4,7,10,13-pentaazacyclopentadecan-2-yl]acetic acid).
